FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308744032> ?p ?o ?g. }

• W4308744032 endingPage "e58" @default.
• W4308744032 startingPage "e46" @default.
• W4308744032 abstract "Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of olutasidenib, as monotherapy or in combination with azacitidine, in patients with acute myeloid leukaemia or myelodysplastic syndrome, harbouring mutant IDH1.In this phase 1/2, multicentre, open-label clinical trial, we enrolled patients aged 18 years or older with acute myeloid leukaemia or intermediate, high, or very high risk myelodysplastic syndrome harbouring mutant IDH1 at 18 study sites in the USA, Australia, France, and Spain. Other key eligibility criteria included Eastern Cooperative Oncology Group performance status 0-2 with adequate liver and renal function. The primary outcomes were dose-limiting toxicities and the maximum tolerated dose, maximum evaluated dose, and the recommended phase 2 dose of olutasidenib. Olutasidenib was administered orally in doses of 150 mg once daily, 150 mg twice per day, and 300 mg once daily. Azacitidine (75 mg/m2) was administered subcutaneously or intravenously daily for 7 days on, 21 days off. The study was ongoing at the data cutoff (Oct 2, 2019) and is registered with ClinicalTrials.gov, NCT02719574.Patients were enrolled between Aug 8, 2016, and Nov 14, 2018. 78 patients received olutasidenib as monotherapy (n=32) or in combination with azacitidine (n=46). The median follow-up was 8·3 months (IQR 3·1-13·3) for monotherapy and 10·1 months (4·2-15·3) for combination therapy. 16 (50%) of 32 patients in the monotherapy group and 24 (52%) of 46 patients in the combination therapy group were women. Most patients were White (26 [81%] for monotherapy and 31 [67%] for combination therapy). No dose-limiting toxicities were reported in the dose-escalation cohorts and 150 mg twice per day was declared the recommended phase 2 dose on the basis of safety, pharmacokinetics and pharmacodynamics, and clinical activity. The most common (≥20%) grade 3-4 treatment-emergent adverse events with monotherapy were thrombocytopenia (nine [28%] of 32 patients), febrile neutropenia (seven [22%] of 32), and anaemia (seven [22%] of 32); and with combination therapy were thrombocytopenia (19 [41%] of 46), febrile neutropenia (13 [28%] of 46), neutropenia (13 [28%] of 46), and anaemia (nine [20%] of 46). 11 (34%) of 32 patients in the monotherapy group and nine (20%) of 46 patients in the combination therapy group died (most commonly from disease progression [three (9%) of 32 and four (9%) of 46]). No deaths were considered study-drug related. For patients with relapsed or refractory acute myeloid leukaemia, 41% (95% CI 21-64; nine of 22) receiving monotherapy and 46% (27-67; 12 of 26) receiving combination therapy had an overall response. For treatment-naive patients with acute myeloid leukaemia, 25% (1-81; one of four) receiving monotherapy and 77% (46-95; ten of 13) receiving combination therapy had an overall response.Olutasidenib, with or without azacitidine, was well tolerated and showed meaningful clinical activity in patients with IDH1-mutated acute myeloid leukaemia. The results of this phase 1 study provide rationale for the continued evaluation of olutasidenib in multiple patient populations with myeloid malignancies.Forma Therapeutics." @default.
• W4308744032 created "2022-11-15" @default.
• W4308744032 creator A5001550074 @default.
• W4308744032 creator A5003572390 @default.
• W4308744032 creator A5003682435 @default.
• W4308744032 creator A5005591514 @default.
• W4308744032 creator A5008012217 @default.
• W4308744032 creator A5010990164 @default.
• W4308744032 creator A5014336132 @default.
• W4308744032 creator A5015101485 @default.
• W4308744032 creator A5017435311 @default.
• W4308744032 creator A5027520603 @default.
• W4308744032 creator A5028199476 @default.
• W4308744032 creator A5029013179 @default.
• W4308744032 creator A5035222674 @default.
• W4308744032 creator A5037299848 @default.
• W4308744032 creator A5038660651 @default.
• W4308744032 creator A5040373927 @default.
• W4308744032 creator A5042954440 @default.
• W4308744032 creator A5046198086 @default.
• W4308744032 creator A5047486674 @default.
• W4308744032 creator A5049910941 @default.
• W4308744032 creator A5052150142 @default.
• W4308744032 creator A5066185867 @default.
• W4308744032 creator A5066471470 @default.
• W4308744032 creator A5068133376 @default.
• W4308744032 creator A5069987563 @default.
• W4308744032 creator A5072953400 @default.
• W4308744032 creator A5075607061 @default.
• W4308744032 creator A5084409602 @default.
• W4308744032 date "2023-01-01" @default.
• W4308744032 modified "2023-10-15" @default.
• W4308744032 title "Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial" @default.
• W4308744032 cites W1847894796 @default.
• W4308744032 cites W2012588998 @default.
• W4308744032 cites W2054383376 @default.
• W4308744032 cites W2111163869 @default.
• W4308744032 cites W2129510594 @default.
• W4308744032 cites W2154313451 @default.
• W4308744032 cites W2159507916 @default.
• W4308744032 cites W2159731673 @default.
• W4308744032 cites W2551053117 @default.
• W4308744032 cites W2623089849 @default.
• W4308744032 cites W2787911840 @default.
• W4308744032 cites W2806682325 @default.
• W4308744032 cites W2888771996 @default.
• W4308744032 cites W2913322626 @default.
• W4308744032 cites W2950528771 @default.
• W4308744032 cites W2953380463 @default.
• W4308744032 cites W3001216252 @default.
• W4308744032 cites W3021352118 @default.
• W4308744032 cites W3024247862 @default.
• W4308744032 cites W3048827006 @default.
• W4308744032 cites W3095552675 @default.
• W4308744032 cites W3164477864 @default.
• W4308744032 cites W4224290890 @default.
• W4308744032 cites W4376595466 @default.
• W4308744032 doi "https://doi.org/10.1016/s2352-3026(22)00292-7" @default.
• W4308744032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36370742" @default.
• W4308744032 hasPublicationYear "2023" @default.
• W4308744032 type Work @default.
• W4308744032 citedByCount "30" @default.
• W4308744032 countsByYear W43087440322023 @default.
• W4308744032 crossrefType "journal-article" @default.
• W4308744032 hasAuthorship W4308744032A5001550074 @default.
• W4308744032 hasAuthorship W4308744032A5003572390 @default.
• W4308744032 hasAuthorship W4308744032A5003682435 @default.
• W4308744032 hasAuthorship W4308744032A5005591514 @default.
• W4308744032 hasAuthorship W4308744032A5008012217 @default.
• W4308744032 hasAuthorship W4308744032A5010990164 @default.
• W4308744032 hasAuthorship W4308744032A5014336132 @default.
• W4308744032 hasAuthorship W4308744032A5015101485 @default.
• W4308744032 hasAuthorship W4308744032A5017435311 @default.
• W4308744032 hasAuthorship W4308744032A5027520603 @default.
• W4308744032 hasAuthorship W4308744032A5028199476 @default.
• W4308744032 hasAuthorship W4308744032A5029013179 @default.
• W4308744032 hasAuthorship W4308744032A5035222674 @default.
• W4308744032 hasAuthorship W4308744032A5037299848 @default.
• W4308744032 hasAuthorship W4308744032A5038660651 @default.
• W4308744032 hasAuthorship W4308744032A5040373927 @default.
• W4308744032 hasAuthorship W4308744032A5042954440 @default.
• W4308744032 hasAuthorship W4308744032A5046198086 @default.
• W4308744032 hasAuthorship W4308744032A5047486674 @default.
• W4308744032 hasAuthorship W4308744032A5049910941 @default.
• W4308744032 hasAuthorship W4308744032A5052150142 @default.
• W4308744032 hasAuthorship W4308744032A5066185867 @default.
• W4308744032 hasAuthorship W4308744032A5066471470 @default.
• W4308744032 hasAuthorship W4308744032A5068133376 @default.
• W4308744032 hasAuthorship W4308744032A5069987563 @default.
• W4308744032 hasAuthorship W4308744032A5072953400 @default.
• W4308744032 hasAuthorship W4308744032A5075607061 @default.
• W4308744032 hasAuthorship W4308744032A5084409602 @default.
• W4308744032 hasConcept C104317684 @default.
• W4308744032 hasConcept C111113717 @default.
• W4308744032 hasConcept C112705442 @default.
• W4308744032 hasConcept C126322002 @default.
• W4308744032 hasConcept C127848430 @default.
• W4308744032 hasConcept C143998085 @default.

• next